



# Start With Clarity

The RoadMap™ Analysis

# The First Step to Coronary Artery Disease Diagnosis

The RoadMap™ analysis assists CT readers to **accurately<sup>1</sup>, efficiently, and consistently** identify stenoses in the coronary arteries. This anatomic visualization helps readers evaluate coronary CT angiograms (CCTA) before determining the need for an FFR<sub>CT</sub>. The RoadMap analysis easily integrates with HeartFlow's Direct workflow.

## Detect Disease With High Accuracy<sup>1</sup>

The RoadMap analysis helps CT readers diagnose non-invasively and accurately<sup>1</sup> compared to measured QCA angiogram data, ensuring disease is not missed.



Help ensure disease is not missed.



Help diagnose non-invasively and accurately.



“[The RoadMap analysis] is just **making reading easier**. It helps me **focus my search** when reading the case, especially when reading a lot. I look at the RoadMap analysis in parallel to reading [coronary CTAs] and focus mostly on capsules.”


— Edward Danehy, M.D.  
Diagnostic Radiology, Radiology Regional

<sup>1</sup> Compared to measured QCA angiogram data. Data on file.


# Increase Efficiency for CT Readers

The RoadMap™ analysis delivers an anatomic visualization of all the coronary arteries. With the Direct workflow, you will have the anatomic and physiologic information you need to inform your CCTA read.


## How the RoadMap analysis increases efficiency:



Receive a first look with every CCTA for all coronary arteries.



Instantly spot the location and severity of stenosis with color-coded markers.



Efficiently access anatomic and physiologic information.

## Elevate your CCTA Program with consistency


The RoadMap analysis is proven to reduce inter-reader variability.<sup>2</sup> With increased consistency of reads across CT readers, the RoadMap analysis can help CT readers ensure patients receive appropriate subsequent care and confidently determine the need for an FFR<sub>CT</sub>.

### Study design:

- 50 CCTAs read 3 times by certified Level 3 readers and processed 3 times by HeartFlow analysts
- Inter-reader agreement for CAD-RADS stenosis categories was assessed

### Inter-reader Reproducibility

(Overall Kappa for per-vessel % stenosis)



<sup>2</sup> Khasanova E et al. JCCT 2022.

**>50%**  
**better agreement**


between readers when using  
the RoadMap analysis

*Facilitates more consistent reads.*

# Integrate the RoadMap™ Analysis With Ease

The RoadMap analysis integrates seamlessly into the HeartFlow Direct workflow.

- Anatomy + physiology quickly available for all CCTAs
- Provides a preview of severity and location of modeled stenoses  $\geq 30\%$
- $\text{FFR}_{\text{CT}}$  identifies physiologically significant lesions




# Bring Clarity to Every CCTA With the RoadMap™ Analysis...

- Color-coded capsules closely align with CAD-RADS 2.0 and indicate the location and severity of stenosis  $\geq 30\%$  for all vessels  $> 1.8\text{mm}$ .
- Curved planar reformation (CPR) images provided for the LAD, LCX, and RCA with overlaid capsules.
- Presence of plaque depicted on outer wall of anatomy overview image.
- Integration into PACS for workflow convenience.



## ...And Help Guide Treatment Decisions With FFR<sub>CT</sub>

- The AHA / ACC guidelines highlight the use of FFR<sub>CT</sub> in patients with 40-90% stenosis.
- Management plans for over 66% of patients changed after physician received the FFR<sub>CT</sub> analysis compared to CCTA alone.<sup>3</sup>



## 2021 ACC/AHA Guidelines

Intermediate / High Risk Patients



### CCTA

To **diagnose** CAD and **guide treatment decisions**

Class 1 Recommendation  
Level A Evidence

40-90%  
stenosis





### FFR<sub>CT</sub>

To help **guide treatment decisions**

Class 2a Recommendation  
Level B Evidence



# The RoadMap™ Analysis Overview



**Legal Disclaimer:** The information provided by the HeartFlow FFR<sub>CT</sub> and RoadMap Analysis are intended to be used in conjunction with the patient's clinical history, symptoms and other diagnostic tests, as well as the clinician's professional judgment. The HeartFlow FFR<sub>CT</sub> and RoadMap Analysis may not be appropriate for all patients. See their respective indications for use for more information.

The HeartFlow FFR<sub>CT</sub> Analysis has received FDA Clearance, is CE-Marked, and is commercially available in the United States, Europe, Japan and Canada.

The RoadMap Analysis has received FDA Clearance, is CE-Marked, and is commercially available in the United States.

©HeartFlow 2023. All rights reserved. HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc.

194544887 v1



331 E Evelyn Ave, Mountain View, CA 94041 | USA  
 ph: +1.650.241.1221 | info@heartflow.com